CoChat

Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

Open access
Copland, Emma, Canoy, Dexter, Nazarzadeh, Milad, Bidel, Zeinab, Ramakrishnan, Rema, Woodward, Mark, Chalmers, John, Teo, Koon K, Pepine, Carl J, Davis, Barry R, Kjeldsen, Sverre, Sundström, Johan, Rahimi, Kazem, Adler, A, Agodoa, L, Algra, A, Asselbergs, F W, Beckett, N, Berge, E, Black, H, Brouwers, F P J, Brown, M, Bulpitt, C J, Byington, B, Chalmers, J, Cushman, W C, Cutler, J, Davis, B R, Devereaux, R B, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A K, Holman, R R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S E, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L H, Lueders, S, MacMahon, S, Mancia, G, Matsuzaki, M, Mehlum, M H, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C J, Pfeffer, M, Poulter, N R, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J A, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W H, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z Y, Anderson, C, Baigent, C, Brenner, BM, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Pitt, B, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundström, J, Turnbull, F, Viberti, G, Wang, J · 2021 · The Lancet Oncology
Cited by 103

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Some studies have suggested a link between antihypertensive medication and cancer, but the evidence is so far inconclusive. Thus, we aimed to investigate this association in a large individual patient data meta-analysis of randomised clinical trials. METHODS: We searched PubMed, MEDLINE, The Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from Jan 1, 1966, to Sept 1, 2019, to identify potentially eligible randomised controlled trials. Eligible studies were randomised controlled trials comparing one blood pressure lowering drug class with a placebo, inactive control, or other blood pressure lowering drug. We also required that trials had at least 1000 participant years of follow-up in each treatment group. Trials without cancer event information were excluded. We requested individual participant data from the authors of eligible trials. We pooled individual participant-level data from eligible trials and assessed the effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), β blockers, calcium channel blockers, and thiazide diuretics on cancer risk in one-stage individual participant data and network meta-analyses. Cause-specific fixed-effects Cox regression models, stratified by trial, were used to calculate hazard ratios (HRs). The primary outcome was any cancer event, defined as the first occurrence of any cancer diagnosed after randomisation. This study is registered with PROSPERO (CRD42018099283). FINDINGS: 33 trials met the inclusion criteria, and included 260 447 participants with 15 012 cancer events. Median follow-up of included participants was 4·2 years (IQR 3·0-5·0). In the individual participant data meta-analysis comparing each drug class with all other comparators, no associations were identified between any antihypertensive drug class and risk of any cancer (HR 0·99 [95% CI 0·95-1·04] for ACEIs; 0·96 [0·92-1·01] for ARBs; 0·98 [0·89-1·07] for β blockers; 1·01 [0·95-1·07] for thiazides), with the exception of calcium channel blockers (1·06 [1·01-1·11]). In the network meta-analysis comparing drug classes against placebo, we found no excess cancer risk with any drug class (HR 1·00 [95% CI 0·93-1·09] for ACEIs; 0·99 [0·92-1·06] for ARBs; 0·99 [0·89-1·11] for β blockers; 1·04 [0·96-1·13] for calcium channel blockers; 1·00 [0·90-1·10] for thiazides). INTERPRETATION: We found no consistent evidence that antihypertensive medication use had any effect on cancer risk. Although such findings are reassuring, evidence for some comparisons was insufficient to entirely rule out excess risk, in particular for calcium channel blockers. FUNDING: British Heart Foundation, National Institute for Health Research, Oxford Martin School.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00033-4

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 103

Metadata

Authors
Copland, E., Canoy, D., Nazarzadeh, M., Bidel, Z., Ramakrishnan, R., Woodward, M., Chalmers, J., Teo, K. K., Pepine, C. J., Davis, B. R., Kjeldsen, S., Sundström, J., Rahimi, K., Adler, A., Agodoa, L., Algra, A., Asselbergs, F. W., Beckett, N., Berge, E., Black, H., Brouwers, F. P. J., Brown, M., Bulpitt, C. J., Byington, B., Chalmers, J., Cushman, W. C., Cutler, J., Davis, B. R., Devereaux, R. B., Dwyer, J., Estacio, R., Fagard, R., Fox, K., Fukui, T., Gupta, A. K., Holman, R. R., Imai, Y., Ishii, M., Julius, S., Kanno, Y., Kjeldsen, S. E., Kostis, J., Kuramoto, K., Lanke, J., Lewis, E., Lewis, J., Lievre, M., Lindholm, L. H., Lueders, S., MacMahon, S., Mancia, G., Matsuzaki, M., Mehlum, M. H., Nissen, S., Ogawa, H., Ogihara, T., Ohkubo, T., Palmer, C., Patel, A., Pepine, C. J., Pfeffer, M., Poulter, N. R., Rakugi, H., Reboldi, G., Reid, C., Remuzzi, G., Ruggenenti, P., Saruta, T., Schrader, J., Schrier, R., Sever, P., Sleight, P., Staessen, J. A., Suzuki, H., Thijs, L., Ueshima, K., Umemoto, S., van Gilst, W. H., Verdecchia, P., Wachtell, K., Whelton, P., Wing, L., Woodward, M., Yui, Y., Yusuf, S., Zanchetti, A., Zhang, Z. Y., Anderson, C., Baigent, C., Brenner, B., Collins, R., de Zeeuw, D., Lubsen, J., Malacco, E., Neal, B., Perkovic, V, Pitt, B., Rodgers, A., Rothwell, P., Salimi-Khorshidi, G., Sundström, J., Turnbull, F., Viberti, G., & Wang, J.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2021-04
Volume
22
Issue
4
Pages
558-570
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3145416765
Cited by
103
References
19
FWCI
4.80
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00033-4
The paper
Copland, E., Canoy, D., Nazarzadeh, M., Bidel, Z., Ramakrishnan, R., Woodward, M., Chalmers, J., Teo, K. K., Pepine, C. J., Davis, B. R., Kjeldsen, S., Sundström, J., Rahimi, K., Adler, A., Agodoa, L., Algra, A., Asselbergs, F. W., Beckett, N., Berge, E., . . . Wang, J. (2021). Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00033-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.